Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review.

Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X.

Eur Respir J. 2018 Nov 29;52(5). pii: 1801393. doi: 10.1183/13993003.01393-2018. Print 2018 Nov.

2.

Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment.

Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X.

Curr Med Res Opin. 2018 Dec;34(12):2075-2088. doi: 10.1080/03007995.2018.1505352. Epub 2018 Aug 16.

PMID:
30047292
3.

Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.

Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J, Kerkhof M, Ow M, Tran TN.

Allergy. 2019 Feb;74(2):273-283. doi: 10.1111/all.13556. Epub 2018 Nov 20.

4.

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.

Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB.

Thorax. 2018 Feb;73(2):116-124. doi: 10.1136/thoraxjnl-2017-210531. Epub 2017 Sep 16.

5.

Green chemicals from pulp production black liquor by partial wet oxidation.

Muddassar HR, Melin K, de Villalba Kokkonen D, Riera GV, Golam S, Koskinen J.

Waste Manag Res. 2015 Nov;33(11):1015-21. doi: 10.1177/0734242X15602807. Epub 2015 Sep 16.

PMID:
26377325

Supplemental Content

Support Center